Description
Buy Wegovy (Semaglutide) Online – The UK’s First Licensed GLP-1 Weight Loss Injection
What is Wegovy?
Wegovy is a prescription-only medication developed by Novo Nordisk that has transformed the landscape of weight management. It contains semaglutide, a human glucagon-like peptide-1 (GLP-1) analogue produced using recombinant DNA technology. As a GLP-1 receptor agonist, Wegovy works by binding to and activating GLP-1 receptors in the brain, pancreas, and gastrointestinal tract . This unique mechanism reduces appetite, promotes satiety, enhances glucose-dependent insulin secretion, and delays gastric emptying.
How Does Wegovy Work?
Wegovy’s mechanism of action is scientifically proven. The active ingredient, semaglutide, mimics the GLP-1 hormone naturally produced in the gut. This activation of the GLP-1 receptor works through multiple pathways: it reduces hunger signals in the hypothalamus, slows gastric emptying to promote prolonged fullness, and increases insulin secretion while suppressing glucagon release. The Mayo Clinic confirms that these combined effects lead to significant and sustainable weight loss when used alongside a reduced-calorie diet and increased physical activity.
Clinical Efficacy: Proven Weight Loss Results
Wegovy has demonstrated exceptional weight loss results in the landmark STEP clinical trial programme. The STEP 1 study, published in the New England Journal of Medicine, showed that participants taking Wegovy 2.4mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. The STEP 2 trial in patients with type 2 diabetes showed average weight loss of 9.6%, while the STEP 3 trial combined with intensive behavioural therapy achieved 16.0% weight loss.
In January 2026, the MHRA approved a new 7.2mg maximum weekly dose of Wegovy. The STEP UP clinical trial found that this higher dose delivered an average weight loss of 20.7%, with approximately one third of participants achieving a weight loss of 25% or more after 72 weeks. The BMJ reported that this brings the efficacy of semaglutide closer to that of tirzepatide, providing patients with more options for achieving meaningful weight loss.
Cardiovascular Benefits
Beyond weight loss, Wegovy offers significant cardiovascular benefits. The landmark SELECT trial, published in the New England Journal of Medicine, demonstrated that Wegovy 2.4mg reduced the risk of major adverse cardiovascular events (MACE) by 20% in adults with established cardiovascular disease and overweight or obesity. The trial showed reductions in systolic blood pressure by 3.82 mmHg, total cholesterol by 4.63%, and improvements in HDL cholesterol and other cardiometabolic risk factors [citation:10]. The OASIS 4 trial also showed that oral semaglutide improved glycemic parameters and cardiovascular risk factors regardless of weight loss amount.
Comparison with Other Treatments
Wegovy has been compared favourably to other weight loss medications. In the SURMOUNT-5 study, tirzepatide led to 20.2% weight loss compared to 13.7% with semaglutide. However, the new 7.2mg dose of Wegovy brings its efficacy closer to tirzepatide, with weight loss of 20.7%. Wegovy has the advantage of being the first GLP-1 agonist specifically licensed for weight management in the UK and has established cardiovascular outcome data [citation:9][citation:10]. The BMJ notes that the higher dose provides clinicians with greater flexibility to tailor treatment, supporting evidence-based approaches to improve health outcomes.
Important Safety Information
Boxed Warning
Wegovy carries a Boxed Warning regarding the risk of thyroid C-cell tumors. In rodent studies, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors. The human relevance of this finding has not been determined . Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Most Common Side Effects
Clinical studies have shown that the most common adverse reactions (reported in ≥5% of patients) include nausea, vomiting, diarrhoea, constipation, abdominal pain, and headache. The Mayo Clinic notes that most gastrointestinal side effects occur when increasing the dose and decrease over time as the body adjusts. In the STEP UP trial, 70.8% of those taking 7.2mg experienced gastrointestinal effects, compared to 61.2% on 2.4mg .
Serious Warnings and Precautions
Wegovy has been associated with the following serious risks: Acute Pancreatitis (discontinue immediately if suspected), Hypoglycemia (risk increases when used with insulin or sulfonylureas), Hypersensitivity Reactions, Acute Kidney Injury (due to volume depletion), and Acute Gallbladder Disease .
Eligibility and Indications
Wegovy is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with:
- Initial BMI of ≥ 30 kg/m² (obesity), or
- Initial BMI of ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity, including:
- Age 18 years or over
Dosage and Administration
Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen. The dosing schedule follows a structured titration approach:
- Month 1 (Starting dose): 0.25 mg once weekly for 4 weeks
- Month 2: 0.5 mg once weekly for 4 weeks
- Month 3: 1.0 mg once weekly for 4 weeks
- Month 4: 1.7 mg once weekly for 4 weeks
- Maintenance dose: 2.4 mg once weekly
- New higher dose (from 2026): Up to 7.2 mg once weekly, administered as three 2.4mg injections or a single 7.2mg pen
Injection sites should be rotated (abdomen, thigh, or upper arm) and administration may occur at any time of day, with or without meals.
Wegovy Treatment Pricing
Wegovy is available through private prescription in the UK. Pricing for a 4-week supply typically includes full clinical assessment and ongoing support:
| Dose | Standard Price (4-week supply) |
|---|---|
| 0.25 mg (Starting) | £169.00 |
| 0.5 mg | £189.00 |
| 1.0 mg | £189.00 |
| 1.7 mg | £259.00 |
| 2.4 mg (Maintenance) | £309.00 |
Prices are indicative and may vary by provider. All prices include full clinical assessment and ongoing clinical support .
Frequently Asked Questions (FAQs)
1. How much weight can I expect to lose on Wegovy?
Based on clinical trial results, patients on the standard 2.4mg dose lose an average of 15-17% of their body weight over 68 weeks. The new 7.2mg dose has shown average weight loss of 20.7% over 72 weeks. Individual results vary based on factors including dose, adherence to lifestyle changes, and overall health.
2. How quickly does Wegovy start working?
Weight loss is typically gradual, with most significant results seen over 68-72 weeks. However, many patients report reduced appetite and hunger within the first few weeks of starting treatment.
3. What is the difference between Wegovy and Ozempic?
Both contain semaglutide, but they are approved for different indications and doses. Wegovy is licensed specifically for weight management at doses up to 2.4mg (and now 7.2mg), while Ozempic is licensed for type 2 diabetes at lower doses (up to 1mg). Wegovy has also demonstrated cardiovascular benefits in patients with established heart disease.
4. What are the most common side effects of Wegovy?
The most common side effects are gastrointestinal and include nausea, vomiting, diarrhoea, constipation, and abdominal pain. The BMJ notes that 70.8% of those on 7.2mg experienced gastrointestinal effects, but most are temporary and decrease over time.
5. Is Wegovy safe for long-term use?
Wegovy has been studied extensively with follow-up periods of up to 3.4 years showing sustained weight loss and cardiovascular benefits [citation:9]. The safety profile is well-established, with the main concern being the Boxed Warning regarding thyroid C-cell tumors, a risk primarily observed in animal studies.
6. Can Wegovy be used with other medications?
Wegovy may interact with other medications. Concomitant use with insulin or sulfonylureas may increase the risk of hypoglycemia. Oral birth control pills may not work as effectively during the first 4 weeks of treatment and for 4 weeks after each dose increase. Patients should discuss all medications with their healthcare provider.
7. What happens if I miss a dose of Wegovy?
If you miss a dose and it is within 5 days of your scheduled time, take it as soon as possible. If more than 5 days have passed, skip the missed dose and take your next dose on your regular day. Never take two doses within 3 days of each other.
8. Who is eligible for Wegovy treatment?
Wegovy is indicated for adults with a BMI of 30 kg/m² or above (obese), or a BMI of 27 kg/m² or above (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease.
9. Is Wegovy covered by the NHS?
Wegovy is available through the NHS under NICE guidance for patients meeting specific criteria, including a BMI of 35 or above and at least one weight-related comorbidity. However, the new 7.2mg dose is not yet available on the NHS pending NICE appraisal. Access is typically through specialist weight management services.
10. Can I stop taking Wegovy once I reach my weight loss goal?
Stopping Wegovy typically leads to weight regain. The STEP 1 trial showed that weight loss is not sustained after discontinuation. Discuss maintenance strategies with your healthcare provider to create a plan for long-term weight management. The NIH notes that for sustained benefit, patients will likely need to remain on treatment.
References and Additional Resources
For more information about Wegovy, consult these reputable sources:
Reviews
There are no reviews yet.